| Literature DB >> 20436730 |
J Janifer1, S Geethalakshmi, K Satyavani, V Viswanathan.
Abstract
This study was done to determine the prevalence of lower urinary tract infection (UTI), the causative pathogens, their antimicrobial pattern, and the recurrence of infection in type 2 diabetic subjects. A total of 1157 (M: F 428: 729) type 2 diabetic subjects were selected for this study. Midstream urine specimens were collected and the culture tests were done by a quantitative method whereas antimicrobial sensitivity was determined by using the Kirby-Bauer method. A significant colony count was seen in 495 (42.8%) subjects and an insignificant count in 350 (30.3%) subjects; there were a few cases of recurrent UTI. Women (47.9%) had a significantly higher prevalence of UTI than men (34.1%) (chi(2) = 20.3, P < 0.0001). Except for BMI, UTI was significantly associated with age, duration of diabetes, and poor glycemic control in both sexes. About 533 pathogens of gram positive and gram negative bacilli were isolated from 495 subjects in this study. Escherichea coli (E. coli) was the most commonly found organism. Gram negative pathogens were found to be highly sensitive to sulbactum / cefoperazone and piperacillin / tazobactum. The prevalence of UTI was significantly higher in women than men with E. coli being the major isolated pathogen. Gram negative pathogens were highly sensitive to sulbactum / cefoperazone and piperacillin / tazobactum.Entities:
Keywords: Antimicrobial pattern; causative pathogens; lower urinary tract infection; prevalence; type 2 diabetes
Year: 2009 PMID: 20436730 PMCID: PMC2859475 DOI: 10.4103/0971-4065.57107
Source DB: PubMed Journal: Indian J Nephrol ISSN: 0971-4065
Genderwise prevalence of urinary tract infection
| Men | |||
|---|---|---|---|
| Total ( | 495 | 42.8 | |
| Men ( | 146 | 34.1 | 20.3, < 0.0001 |
| Women ( | 349 | 47.9 |
Clinical characteristics of subjects with significant urinary tract infection
| Clinical characteristics | Men | Women |
|---|---|---|
| Age (years) | ||
| <45 ( | 12 (8.2) | 34 (9.7) |
| 45–55 ( | 35 (23.9) | 102 (29.2) |
| >55 ( | 99 (67.8) | 213 (61) |
| χ2 = 116.6, | χ2 = 206.6, | |
| Duration of diabetes (years) | ||
| <10 ( | 61 (41.8) | 148 (42.4) |
| ≥10 ( | 85 (58.2) | 201 (57.6) |
| Z = 1.8, | Z = 2.69, | |
| BMI (kg/m2) | ( | ( |
| <25 ( | 59 (51.7) | 93 (32.5) |
| ≥25 ( | 55 (48.2) | 193 (67.5) |
| Z = 0.18, | Z = 5.5, | |
| HbA1c(%) | ||
| <8 ( | 22 (19.3) | 63 (22) |
| 8–9 ( | 15 (13.2) | 49 (17.1) |
| ≥9 ( | 74 (64.9) | 177 (61.9) |
| χ2 = 54.1, | χ2 = 101.7, | |
Men vs Women χ2 = 11.99; P < 0.0005; Values are n (%)
Figure 1Panel a shows the percentage-wise distribution of gram negative bacilli among UTI subjects
Figure 1Panel b shows the percentage-wise distribution of gram positive cocci among UTI subjects
Antimicrobial pattern of gram positive cocci and gram negative bacilli
| Antimicrobials | Gram positive cocci ( | Gram negative bacilli ( |
|---|---|---|
| Amikacin | 29 | 65 |
| Netillin | 42 | 67 |
| Tobramycin | 14 | 30 |
| Sulbactum / cefoperazone | 75 | 91 |
| Pipercillin / tazobactum | 66 | 83 |
| Ciprofloxacin | 33 | 62 |
| Ofloxacin | 50 | 23 |
| Norfoxacin | 15 | 20 |
| Cefoperazone | 35 | 33 |
| Ceftzoxime | 48 | 62 |
| Cefotaxime | 63 | 51 |